We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Institute for Clinical and Economic Review has been a thorn in pharma’s side for years, with its reviews often concluding drug launches are priced too high. Now, the pain for pharma could spread.
The Institute for Clinical and Economic Review has been a thorn in pharma’s side for years, with its reviews often concluding drug launches are priced too high. Now, the pain for pharma could spread.